Menu
The Sample and Data Usage Committee reviews newly submitted project proposals in order to analyze its alignment with the aim of the project which originated the sample or data collection requested, its technical/ ethical viability, and its potential scientific impact. The Sample and Data Usage Committee is composed by the Head of Translational Operations, the Head of Clinical Operations, the Head of the Data Management Center, the General Manager of EF CLIF, and the EF CLIF Director. The Principal Investigator(s) of the project(s) samples and data are requested from also contribute to the evaluation and decision making process of granting access to datasets and samples of interest available in the EF CLIF databases and biobank.
| Position | Name / Affiliation | Year appointment |
|---|---|---|
| Ex officio (Head of Translational Operations) | Joan Clària, PhD EF CLIF, Spain | 2022 |
| Ex officio (Head of Clinical Operations) | Javier Fernández, PhD EF CLIF, Spain | 2022 |
| Ex officio (Head of the Data Management Center) | Cristina Sánchez-Garrido EF CLIF, Spain | 2022 |
| Ex officio (General Manager) | Anna Bosch, PhD EF CLIF, Spain | 2022 |
| Ex officio (Director) | Richard Moreau, MD EF CLIF, Spain | 2022 |
| Co-opted members | Alberto Farias, MD, PhD Hospital das Clínicas, Brazil | 2022 |
| Thierry Gustot, MD, PhD CUB Hôpital Erasme, Belgium | 2022 | |
| Rajiv Jalan, MD, PhD University College London, UK | 2022 | |
| Gautam Mehta, MD, PhD University College London, UK | 2022 | |
| Pierre-Emmanuel Rautou, MD, PhD Hôpital Beaujon AP-HP, France | 2022 | |
| Jonel Trebicka, MD, PhD University Hospital Münster, Germany | 2022 |
This page lists independent investigator-led projects approved by the Samples and Data Usage Committee in the current fiscal year.
Marijke Peetermans, UZ Leuven, Belgium
Subphenotypes of patients with cirrhosis and sepsis
Emmanuel Weiss, Centre de recherche sur l’inflammation UMR 1149, France
Clonal hematoposieses as a predictor of the clinical course of patients with acutely decompensated cirrhosis
Maria Pilar Ballester, Hospital Clínico Universitario de Valencia, Spain
Evaluation of factors defining the natural history and response to therapy of patients hospitalized with an acute episode of hepatic encephalopathy
Rudolf Stauber, Medical University of Graz, Austria
HDL-based prognostic models for prediction of short-term survival in acutely decompensated cirrhosis
Marijke Peetermans, UZ Leuven, Belgium
Subphenotypes of patients with cirrhosis and sepsis
Emmanuel Weiss, Centre de recherche sur l’inflammation UMR 1149, France
Clonal hematoposieses as a predictor of the clinical course of patients with acutely decompensated cirrhosis
Maria Pilar Ballester, Hospital Clínico Universitario de Valencia, Spain
Evaluation of factors defining the natural history and response to therapy of patients hospitalized with an acute episode of hepatic encephalopathy
Rudolf Stauber, Medical University of Graz, Austria
HDL-based prognostic models for prediction of short-term survival in acutely decompensated cirrhosis
Jun Li, Zhejiang University School of Medicine, China
Validation the effectiveness of the COSSH-ACLF criteria and prognostic score in non-Asian ACLF populations
Jonel Trebicka and Wenyi Gu, University Hospital Münster, Germany
Task 6 in MICROB-PREDICT : Address geographic and gender differences, aging and effects of drugs in the progression of liver diseases
Maria Papp, University of Debrecen, Poland
Can replacing the whole blood cell count with neutrophil to limphocyte ration improve the predictive performance of the CLIF-C AD score?
Download list of projects approved by the Samples and Data Usage Committee to date
European Foundation for the Study of
Chronic Liver Failure
Avinguda Diagonal 477, 11th floor
08036 Barcelona, Spain
Tel: +34 93 227 14 00
Email: Send us an email
© European Foundation for the Study of Chronic Liver Failure 2024
